Lowest Price Guaranteed
Pages
198
Last Updated
August 2025
View Count
5674
The global PCSK9 inhibitors market, valued at USD 2.41 billion in 2024, is estimated to reach USD 2.91 billion in 2025 and USD 13.35 billion by 2035, representing a compounded annual growth rate (CAGR) of 16.5% during the forecast period.
 |
To learn more about this report, request a free sample copy
PCSK9 (proprotein convertase subtilisin / kexin type 9) is a form of serine protease that target LDL (low-density lipoprotein) receptor to degrade it and reduce the ability of liver to eliminate LDL-cholesterol in blood. These inhibitors initiate the action by binding to the PCSK9 instead of binding to the LDL receptors present of on the liver surface, facilitating the clearance of LDL cholesterol from the blood. Healthcare experts generally PCSK9 inhibitors to the patients if other available treatment does not work or have any genetic conditions that raises the risk of high cholesterol.
It is important to highlight here that high cholesterol can cause serious health issues, such as heart stroke and chronic kidney disease. As per the World Health Organization, high cholesterol is anticipated to cause around 2.6 million deaths globally. Sedentary lifestyle and unhealthy eating habits have contributed to the growing risk of high cholesterol across the globe.
Driven by the growing risk, there is a surge in the demand for advance inhibitor-based drugs that helps to reduce LDL-cholesterol level in the blood. PCSK9 inhibitors emerge as a potential solution for the patients suffering from high cholesterol. Some of the notable examples of PCSK9 inhibitors that has received approval from the USFDA are Praluent® (Alirocumab), Repatha® (Evolocumab), Leqvio® (Inclisiran) and SINTBILO® (Tafolecimab). In addition, PCSK9 inhibitors also helps to reduce the risk of heart stroke, myocardial infarction and unstable angina in patients with cardiovascular diseases.
It is important to highlight here that several industrial players are currently focusing on the development of advanced PCSK9 inhibitors and exploring more therapeutic potential. For instance, in June 2025, Merck (US) announced positive results of enlicitide decanoate, an investigation oral PCSK9 from the first two of three phase III clinical trials evaluating safety and efficacy. This drug is being evaluated under clinical trial for the treatment of adults with hyperlipidemia on lipid-lowering therapies. These positive outcomes and ongoing research have catered the attention of industrial players to develop and explore more therapeutic potential of PCSK9 inhibitors.
It is important to mention here that similar to AZD0780 several PCSK9 inhibitors are presently several drugs are clinical trials which we believe will receive the USFDA approval during the upcoming years. Driven by the growing pipeline of inhibitors are rising research, the market for PCSK9 inhibitors is likely to expand at a substantial rate, offering opportunities to industrial players for making considerable investments.
The market report highlights the invaluable information about leading players of the PCSK9 inhibitors industry who are presently active across different segments of the market as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | $2.91 Billion | |
| Market Size 2035 | $13.35 Billion | |
| CAGR (till 2035) | 16.5% | |
| Key Drugs |
|
|
| Type of Modality |
|
|
| Type of Application |
|
|
| Distribution Channel |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the PCSK9 inhibitors market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The PCSK9 inhibitors market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as key drug, type of modality, type of application, distribution channel, geographical region, and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of drugs, the global PCSK9 inhibitors market is segmented into Praluent® (Alirocumab), Repatha® (Evolocumab), Leqvio® (Inclisiran) and SINTBILO® (Tafolecimab). Repatha and Praluent are antibody therapeutics that inhibit PCSK9, whereas Leqvio is a small interfering RNA (siRNA) therapy that works through PCSK9 gene silencing. According to our projection, currently Repatha® is dominating the industry by holding the highest MARKET share. Repatha® has demonstrated high safety profile and efficacy in reducing LDL cholesterol level in patients. Furthermore, Repatha® by Amgen (US) has received the USFDA approval and the researchers’ team at Amgen (US) is currently expanding research on this therapeutic to explore its usage for the treatment of cardiovascular conditions. In addition, Repatha® has recorded a 41% increase in sales, reaching USD $656 million in the first quarter of 2025 as per Amgen (US) report.
However, Praluent® (Alirocumab) developed by Regeneron Pharmaceuticals (Sanofi, US) has shown significant growth potential and is poised to grow at a high CAGR driven by ongoing research and proven efficacy for treating patients with high LDL-cholesterol level.
This segment highlights the distribution of global PCSK9 inhibitors market based on the type of modality into monoclonal antibodies and small interfering RNA. Among these, monoclonal antibodies account for the highest share (nearly 80%) of the market. This can be attributed to the growing approval of monoclonal antibodies-based inhibitor drugs such as Praluent® (Alirocumab), and Repatha® (Evolocumab) from the USFDA to treat patients with high risk of LDL-cholesterol. Furthermore, monoclonal antibodies have shown higher efficacy in inhibiting the action of PCSK9 to lower down the level of LDL cholesterol in the blood.
Although monoclonal antibodies remain the dominant category driven by their higher efficacy and safety profile, small interfering RNA is also an emerging class of PCSK9 inhibitors to reduce the lipid level. Recently, Inclisiran (Leqvio ®), a lipid-lowering novel drug developed by Novartis (Switzerland), has been approved by the USFDA for the treatment of LDL-cholesterol. It is a siRNA (a type of RNAi therapeutic) specific for PCSK9 that has the capability to prevent translation of PCSK9 messenger RNA, thereby helping to reduce the concentration of LDL-cholesterol in blood. Leqvio was the fastest growing therapeutic for Novartis (Switzerland) in terms of revenue growth during the period 2023-2024, showing a growth of 112%. Driven by higher specificity and ongoing approval, this segment will continue to grow at a higher CAGR during the projected period.
The global market is categorized based on the type of application into primary hyperlipidemia, familial hypercholesterolemia and cardiovascular conditions. According to our PCSK9 inhibitors market forecast, familial hypercholesterolemia accounts for the highest share (nearly 45%) of the market. This can be attributed to the higher adoption of PCSK9 inhibitors for the treatment of patients with familial hypercholesterolemia. It is a genetic condition which results in a higher LDL-cholesterol level in the blood. Familial hypercholesterolemia is difficult to manage with traditional therapeutics. PCSK9 inhibitors have shown greater efficacy in treating patients with familial hypercholesterolemia which is likely to be a key factor for the highest share.
However, in the long run, cardiovascular conditions segment is likely to grow at a higher CAGR during the forecast period. Currently, key players are exploring the PCSK9 inhibitors across various cardiovascular conditions such as heart stroke and diseases. PCSK9 inhibitors also help to reduce plaque progression, reducing atherosclerotic diseases, which is anticipated to cater the attention of key players for exploring more therapeutic potential of PCSK9 inhibitors.
Based on the distribution channel, the global PCSK9 inhibitors market is distributed across hospitals, specialty clinics, retail pharmacy and online pharmacy. According to our projection, hospitals account for the highest PCSK9 inhibitors market share (over 40%). This can be attributed to the fact that hospitals are the primary provider for the treatment of LDL-cholesterol and witness high pool of patients with high cholesterol. Furthermore, hospitals provide advanced infrastructure and experienced doctors where patients can get optimal dosage based on diagnosis reports. Driven by the growing preferences this segment will remain dominant and continue to expand at a higher CAGR during the forecast period.
The global PCSK9 inhibitors market is distributed across different geographical regions such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Among these, currently North America is dominating the market, accounting for over 40% of the overall revenue share. This can be attributed to the increasing research on PCSK9 inhibitors for targeting different disease indications beyond cholesterol reduction. Moreover, North America has the highest number of patients with high cholesterol and cardiac diseases which is responsible for the demand for PCSK9 inhibitors for the treatment of patients.
However, in the long run, we believe that the market for PCSK9 inhibitors in Asia-Pacific region is expected to grow at a higher CAGR during the forecast period. This is attributed to the growing number of patients with heart diseases and cholesterol that require advanced inhibitor-based drugs for the treatment. Additionally, growing expenditure by government and healthcare organizations to advance healthcare infrastructure has further supported the growth of market in this region.
The “PCSK9 Inhibitors Market: Industry Trends and Global Forecasts, till 2035” research report features an extensive study of the focus on competitive landscape of strategic initiatives, emerging mega trends, big pharma initiatives, company profiles and key drivers and restraints. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the PCKS inhibitors industry. Key takeaways of the market data analysis are briefly discussed below.
Currently, the global market landscape is highly solidified with the presence of several well-established players and startups. The current focus of industrial players is on the development of advanced PCSK9 inhibitors to target primary hypercholesterolemia and cardiovascular conditions. In order to leverage the competitive edge, the key players in the industry are taking strategic initiatives followed by collaborations, partnerships and latest developments. For instance, in April 2024, the USFDA has approved NEXLIZET® and NEXLETOL® drugs which can be used alone or in combination with LDL-C lowering drugs to reduce the level of cholesterol in adults having primary hyperlipidemia and familial hypercholesterolemia. The increasing approval of drugs from the USFDA for treating LDL-cholesterol has catered the attention of industrial players to drive innovation in this field. Overall, the PCSK9 inhibitors market will remain competitive throughout the projected period driven by ongoing research and rising approval of the drugs.
Some of the solid drivers that are propelling the market growth during the projected period include high incidence of cardiovascular diseases and cholesterol worldwide. As per a report published by the World Health Organization, nearly 1.8 billion adults across the globe are at greater risk of developing serious heart diseases due to insufficient physical activities. However, one major concern of rising risk of heart disease is high cholesterol. It is important to highlight here that high cholesterol results into plaque buildup in the arteries, as a result the arteries become narrow and lead to blood flow reduction. Lack of accurate blood supply leads to heart stroke. Thus, rising incidence of high cholesterol and cardiovascular diseases has underscored the demand for PCSK9 inhibitors to treat patients, which is anticipated to be a key driver for the market.
Drug developers are also focusing on the development of easier to administer oral PCSK9 inhibitors. AstraZeneca (UK) is one of the players with oral PCSK9, AZD0708, in phase II clinical trials for dyslipidemia.
Merck (US) also has phase III stage molecule MK-0616 under evaluation for adults with hypercholesterolemia.
As stated by Christie M. Ballantyne, MD, of Baylor College of Medicine in Houston “If we're able to somehow make it so that we can easily prescribe these drugs to the patients who need them and that the patients can get the medications without so many steps and so much hassle, but I hope that the future will allow us to use these drugs much more easily.” The approval of oral PCSK9 inhibitors will be a key driver for market growth.
Despite high demand, some of the biggest challenges that hinder market progress is the high cost associated with PCSK9 inhibitors. These advanced therapeutic inhibitors are relatively expensive than traditionally available drugs, which limit the adoption across wide range of population. For instance, the cost of Repatha® is around USD 561.49 per month, which sums up around USD 6,000 in a year. The high cost might act as a significant barrier for patients specifically with familial hypercholesteremia or those who require long term treatment. In addition, stringent guidelines associated with the approval of drug may delay the approval of therapeutic drugs.
Some of the notable market growth factors include high demand for precision medicine and expanding usage of PCSK9 inhibitors for other disease indications beyond cardiovascular conditions. Earlier, PCSK9 inhibitors were known for reducing the LDL cholesterol level and cardiovascular diseases. However, several research suggest that these inhibitor-based drugs can also offer benefit in treating disease indications that are influenced by the high cholesterol level. Such as non-alcoholic fatty liver disease and statin associated muscle pains. Driven by the expanding clinical applications of PCKS9 inhibitors, we believe the global market for PCSK9 inhibitors is likely to grow at a steady rate during the forecast period.
The global PCSK9 inhibitors market is currently expected to be valued at USD 2.91 billion and is projected to reach USD 13.35 billion by 2035. Driven by the rising incidence of high cholesterol and heart diseases, the demand for PCSK9 inhibitors has significantly increased, which is expected to drive the market at a CAGR of 16.5% during the forecast period.
It is important to highlight here that several industrial players are entering into the market to accelerate commercialization and global availability of the drugs. In September 2023, Hasten Biopharmaceutical licensed the development and commercialization rights to LIB Therapeutics (US)’ lerodalcibep in Greater China region. Owing to the ongoing initiatives, growing understanding of positive impact of PCSK9 inhibitors on cholesterol levels and strong pipeline, we believe that the market will remain competitive throughout the projected period.
Examples of key players engaged in this domain (which have also been captured in this report) include AstraZeneca (UK), Amgen (US), Alnylam (US), Cyon Therapeutics, Daiichi Sankyo (Japan), Eli Lilly, Ionis Pharmaceuticals (US), Innovent (China), LIB Therapeutics (US), Merck (US), Novartis (Switzerland), Pfizer (US), Roche (Switzerland), and Shanghai Junshi Biosciences (China). This market report includes an easily searchable excel database of all the companies focusing on the development of PCSK9 inhibitors.
Several recent developments have taken place in the PCSK9 market. We have outlined some of these recent initiatives below.